{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:17:54Z","timestamp":1791908274533,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["2012.WO42.C157"],"award-info":[{"award-number":["2012.WO42.C157"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Breast Cancer Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Questionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health\/QoL scores indicate high functioning levels\/high QoL; high symptom-focused measures scores indicate high symptoms\/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD: 21), better than in female BC reference data (62, SD: 25). Common symptoms in male BC were fatigue (22, SD: 24), insomnia (21, SD: 28), and pain (16, SD: 23), for which women\u2019s mean scores indicated more burdensome symptoms at 33 (SD: 26), 30 (SD: 32), and 29 (SD: 29). Men\u2019s mean sexual activity score was 31 (SD: 26), with less sexual activity in older patients or advanced disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>QoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad152","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T15:56:17Z","timestamp":1686671777000},"page":"e877-e883","source":"Crossref","is-referenced-by-count":13,"title":["Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085\/TBCRC029\/BIG2-07\/NABCG)"],"prefix":"10.1093","volume":"28","author":[{"given":"Carolien P","family":"Schr\u00f6der","sequence":"first","affiliation":[{"name":"Department Medical Oncology, Netherlands Cancer Institute Amsterdam and University Medical Center Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"van Leeuwen-Stok","sequence":"additional","affiliation":[{"name":"Dutch Breast Cancer Trialists\u2019 Research Group (BOOG) , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Breast Unit, Champalimaud Clinical Center\/Champalimaud Foundation , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbro","family":"Linderholm","sequence":"additional","affiliation":[{"name":"Department of Oncologym , Sahlgrenska University Hospital, Gothenburg, Sweden and Swedish Association of Breast Oncologists (SABO) , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Johns Hopkins , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Bjelic-Radisic","sequence":"additional","affiliation":[{"name":"Breast Unit, Helios University Clinic, Wuppertal, University Witten\/Herdecke , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group , Porto Alegre , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel H","family":"Abreu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bozovic-Spasojevic","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology and Radiology , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"den Hoed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Elisabeth-TweeSteden Ziekenhuis , Tilburg , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafke H","family":"Honkoop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Isala , Zwolle , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Los","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, St. Antonius Ziekenhuis , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose P","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke J","family":"Smilde","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jeroen Bosch Ziekenhuis\u2019s Hertogenbosch , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette W G","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Martini Ziekenhuis , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6908","authenticated-orcid":false,"given":"Catherine","family":"Van Poznak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije M","family":"Vleugel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Waterlandziekenhuis , Purmerend , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"Yung","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Department of Breast Medical Oncology, MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-332X","authenticated-orcid":false,"given":"Kathryn J","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"14","key":"2023100311172830800_CIT0001","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMc1809194","article-title":"Breast cancer in men","volume":"379","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2023100311172830800_CIT0002","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1634\/theoncologist.2019-0871","article-title":"Exclusion of men from randomized phase III breast cancer clinical trials","volume":"25","author":"Corrigan","year":"2020","journal-title":". The Oncologist"},{"issue":"1","key":"2023100311172830800_CIT0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-022-06543-1","article-title":"Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb complement-1 trial","volume":"193","author":"Campone","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2023100311172830800_CIT0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"2023100311172830800_CIT0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-008-0053-y","article-title":"The rising incidence of male breast cancer","volume":"115","author":"Speirs","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2023100311172830800_CIT0006","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/bcr2930","article-title":"Male breast carcinoma: increased awareness needed","volume":"13","author":"White","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2023100311172830800_CIT0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"16","key":"2023100311172830800_CIT0008","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer: ASCO Guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023100311172830800_CIT0009","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/pon.2001","article-title":"Physical and mental health status and health behaviors in male breast cancer survivors: a national, \u00adpopulation-based, case-control study","volume":"21","author":"Andrykowski","year":"2012","journal-title":"Psychooncology"},{"issue":"1","key":"2023100311172830800_CIT0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-#","article-title":"Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients","volume":"74","author":"Anelli","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"2023100311172830800_CIT0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3747\/co.v17i5.631","article-title":"Endocrine therapy for male breast cancer: rates of toxicity and adherence","volume":"17","author":"Visram","year":"2010","journal-title":"Curr Oncol"},{"issue":"6","key":"2023100311172830800_CIT0012","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/annonc\/mdr459","article-title":"Retrospective review of male breast cancer patients: analysis of \u00adtamoxifen-related side-effects","volume":"23","author":"Pemmaraju","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"2023100311172830800_CIT0013","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-012-2286-z","article-title":"Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer","volume":"136","author":"Xu","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2023100311172830800_CIT0014","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/pon.5356","article-title":"Unmet information needs of men with breast cancer and health professionals","volume":"29","author":"Bootsma","year":"2020","journal-title":"Psychooncology"},{"issue":"1","key":"2023100311172830800_CIT0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000358751","article-title":"Psychological impact of male breast disorders: literature review and survey results","volume":"9","author":"Kipling","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"2023100311172830800_CIT0016"},{"key":"2023100311172830800_CIT0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-0716-1138-8_14","article-title":"Randomized controlled trials 4: Planning, analysis, and interpretation of quality-of-life studies","volume":"2249","author":"Foley","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2023100311172830800_CIT0018","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/0284186X.2013.879998","article-title":"European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies","volume":"53","author":"Hinz","year":"2014","journal-title":"Acta Oncol"},{"issue":"1","key":"2023100311172830800_CIT0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2019.10.031","article-title":"Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer","volume":"125","author":"Mierzynska","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023100311172830800_CIT0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.breast.2012.12.014","article-title":"Quality of life and symptoms in male breast cancer survivors","volume":"22","author":"Ruddy","year":"2013","journal-title":"Breast"},{"issue":"2","key":"2023100311172830800_CIT0021","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10549-012-1970-3","article-title":"Health-related quality of life in male breast cancer patients","volume":"133","author":"Kowalski","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2023100311172830800_CIT0022","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00520-017-3953-8","article-title":"The impact of prostate cancer diagnosis and treatment decision-making on \u00adhealth-related qualit\ty of life before treatment onset","volume":"26","author":"Cuypers","year":"2018","journal-title":"Support Care Cancer"},{"key":"2023100311172830800_CIT0023","first-page":"22","article-title":"Health related quality of life among long-term (&gt;5years) prostate cancer survivors by primary intervention: a systematic review","volume-title":"Health Qual Life Outcomes","author":"Adam","year":"2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e877\/51821259\/oyad152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e877\/51821259\/oyad152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:23:20Z","timestamp":1696332200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/10\/e877\/7197065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad152","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,6,13]]}}}